contact us krjpencn


Our Events

현재 위치: > 뉴스현황 > Our Events

  • 08


    Shanghai - Boston Drug Development International Collaboration Seminar Ended Successfully

    On Aug 24th, Medicilon co-hosted the “Shanghai – Boston Drug Development International Collaboration Seminar” with Shanghai Center of Biomedicine Development and Shanghai Zhangjiang Biotech&Pharmaceutical Base Development Co., Ltd. at Hyatt Regency Hotel, Cambridge, MA.  At the same time, Medicilon hosted the “Client Appreciation Dinner”.  Over 80 guests from pharmaceutical industry and academic institutions in Boston attended the event.

  • 03


    Medicilon Boston Office Officially Opened

    In order to further expand our business, as well as to provide timely and better consulting services to our clients in the Boston area, Medicilon Boston office will start operation from March 1, 2016. Medicilon welcome all the clients to visit our Boston office for further information.

  • 02


    Medicilons VP of Biology was awarded Outstanding Contribution in Reviewing

    Biochemical Pharmacology granted Dr. Jun Wang, Medicilon’s VP of Biology, an “Outstanding Contribution in Reviewing” in recognition of the contribution made to the quality of the journal by Dr. Wang. Dr. Wang has served as Editorial Advisory Board since 2010.

  • 02


    Chemical & Engineering News (C&EN): “Reforming Drug Approval in China”

    The author, Jean-François Tremblay, interviewed Dr. Chunlin Chen, CEO of Medicilon, about his view of the reform. Dr. Chen pointed out that the reform would have a positive impact and brought a healthy and long-lasting development to pharmaceutical industry in China. In addition, Dr. Chen mentioned that Chinese clients of Medicilon business accounted for less than 1% before, but now the Chinese clients accounted half of the Medicilon business.

  • 02


    The special report written by Medicilon CEO, Dr. Chunlin Chen, was posted on Pharmaceutical Forum

    Dr. Chunlin Chen, CEO of Medicilon, wrote a report with the topic of “How to comply both US FDA and CFDA standard of preclinical studies?” and was posted on the first issue of Pharmaceutical Forum of Zhejiang Pharmaceutical Association.